Rapid and fatal acute heart failure induced by pazopanib

Marcke, Cédric Van; Ledoux, Benjamin; Petit, Bénédicte; Seront, Emmanuel

doi:10.1136/bcr-2015-211522

Cited by 15 publications

(9 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite immediate discontinuation of the pazopanib, the patient died. 7 Another report of a young patient without any cardiovascular history or risk factor apart from previous treatment with doxorubicin, who presented with fatal heart failure 4 weeks after initiating treatment with pazopanib has been recently published. 6 It is also unclear whether the cardiac dysfunction induced by pazopanib is reversible or not.…”

Section: Discussionmentioning

confidence: 99%

Rapid and life-threatening heart failure induced by pazopanib

2018

View full text Add to dashboard Cite

A 70-year-old man with history of stage IV renal cell carcinoma, chronic atrial fibrillation on warfarin, coronary artery disease status post-percutaneous coronary intervention resulting in an ischaemic cardiomyopathy with left ventricular ejection fraction of 40%–45%, presented with shortness of breath 10 days after starting pazopanib. Within the first week of starting pazopanib, the patient developed fatigue and progressive dyspnoea on exertion. His symptoms quickly worsened and he had compromised mental status. He was transferred to the intensive care unit (ICU) and intubated due to continued respiratory distress. He was found to be in cardiogenic shock and was started on inotropic support with dobutamine and norepinephrine. With maximum support, the patient was slowly weaned off vasopressors and was successfully extubated on ICU day 9. His hospital stay lasted 29 days with management of multiple medical complications, and he was eventually discharged to a rehabilitation facility.

show abstract

Section: Discussionmentioning

confidence: 99%

Rapid and life-threatening heart failure induced by pazopanib

2018

View full text Add to dashboard Cite

show abstract

“…The inhibition of VEGF or PDGF may cause cardiomyocyte cell death and prevent cardiac remodeling, resulting in cardiac dysfunction (congestive heart failure) [ 82 , 83 ]. Across clinical trials in 799 patients with DTC, renal cell carcinoma (RCC), and hepatocellular carcinoma (HCC), cardiac dysfunction of grade 3 or higher occurred in 3% of lenvatinib-treated patients [ 84 ].…”

Section: Management Of Individual Aesmentioning

confidence: 99%

Management of VEGFR-Targeted TKI for Thyroid Cancer

Enokida

Tahara

2021

Cancers

View full text Add to dashboard Cite

Recent advances in the development of multitarget tyrosine kinase inhibitors (MTKIs), which mainly target the vascular endothelial growth factor receptor (VEGFR), have improved prognoses and dramatically changed the treatment strategy for advanced thyroid cancer. However, adverse events related to this inhibition can interrupt treatment and sometimes lead to discontinuation. In addition, they can be annoying and potentially jeopardize the subjects’ quality of life, even allowing that the clinical outcome of patients with advanced thyroid cancer remains limited. In this review, we summarize the potential mechanisms underlying these adverse events (hypertension, proteinuria and renal impairment, hemorrhage, fistula formation/gastrointestinal perforation, wound healing, cardiovascular toxicities, hematological toxicity, diarrhea, fatigue, and acute cholecystitis), their characteristics, and actual management. Furthermore, we also discuss the importance of related factors, including alternative treatments that target other pathways, the necessity of subject selection for safer administration, and patient education.

show abstract

“…Pazopanib was stopped, but she was worsened dramatically after three days, and the patient died despite inotropic support. 10…”

Section: Patientmentioning

confidence: 99%

Pazopanib-induced fatal heart failure in a patient with unresectable soft tissue sarcoma and review of literature

Karaağaç

Eryılmaz

2019

J Oncol Pharm Pract

View full text Add to dashboard Cite

Introduction Pazopanib, an oral multi-targeted tyrosine kinase inhibitor, is associated with improved outcomes in patients with unresectable or metastatic soft tissue sarcoma. Pazopanib may cause cardiotoxicity such as heart failure. Case report A 50-year-old female patient with no cardiovascular risk factors other than the previous treatment with adriamycin had a baseline left ventricular ejection fraction of 60%. She was receiving pazopanib 800 mg once daily for advanced leiomyosarcoma of the presacral area. On the 60th day of treatment, she presented with fatigue, palpitation, and exertional dyspnea for several days. Echocardiography was performed, and left ventricular ejection fraction was measured as 25%. Pazopanib-induced heart failure was considered and all other possible preliminary diagnoses were excluded. Management and outcome Pazopanib was stopped immediately. Bisoprolol fumarate 5 mg orally once daily, spironolactone 100 mg orally once daily, furosemide 40 mg orally once daily, and ramipril 2.5 mg orally once daily were started. The patient’s symptoms partially improved. Second echocardiography was performed after 15 days, and left ventricular ejection fraction was measured as 35%. But, despite pazopanib was not resumed and cardiac support treatment was administered, she died four weeks after discontinuation of pazopanib due to heart failure. Discussion Pazopanib-induced heart failure may be fatal. Physicians and patients should be aware of the cardiotoxicity risk when managing the use of pazopanib in soft tissue sarcoma.

show abstract

Rapid and fatal acute heart failure induced by pazopanib

Cited by 15 publications

References 9 publications

Rapid and life-threatening heart failure induced by pazopanib

Rapid and life-threatening heart failure induced by pazopanib

Management of VEGFR-Targeted TKI for Thyroid Cancer

Pazopanib-induced fatal heart failure in a patient with unresectable soft tissue sarcoma and review of literature

Contact Info

Product

Resources

About